Overview

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

The study is to optimize the clinical therapeutic pathway of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon gene mutation (IFNA2p.Ala120Thr) and interferon-stimulated genes (ISGs) detection gene spectrum.

Phase:

N/A

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

First People's Hospital of Foshan

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b